Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

BEIJING, Aug. 14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014.

Second Quarter 2014 Financial Highlights (compared to the second quarter 2013)

  • Quarterly sales were $12.1 million, a decrease of 30.7% from $17.5 million in the prior year period. Sales for the first six months were $25.6 million, a decrease of 6.8% YoY from $27.5 million.
  • Gross profit was $9.1 million, a decrease of 33.3% from $13.6 million in the prior year period.
  • Gross margin was 75.0%, compared to 77.9% in the prior year period.
  • Net loss attributable to common stockholders was $2.2 million, or $(0.04) per basic and diluted share, compared to net income attributable to common stockholders of $1.3 million, or $0.02 per basic and diluted share, in the second quarter of 2013.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "While sales were impacted during the second quarter by short-term challenges from the external market environment, we are continuing to grow our sales channels and make strong progress in the development of our pipeline vaccines."

    "In July, we received the first tranche of our RMB 60 million government grant to build a dedicated facility for the production of the EV71 vaccine, which is currently under review by the Center for Drug Evaluation. During the second quarter, we received our clinical trial license for the pneumococcal polysaccharide vaccine (PPV) from the CFDA and expect to begin trials later this year."

    "Although we experienced decreased sales in the second quarter, we remain confident in our ability to execute our proven sales and marketing strategies, and continue to develop new vaccines that are both effective
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related biology technology :

    1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
    2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
    3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
    4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
    5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
    6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
    7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
    8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
    9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
    10. GenVec Reports Second Quarter 2014 Financial Results
    11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
    (Date:11/18/2014)... Calif. , Nov. 18, 2014 Cord ... platinum sponsor of the 10th Annual World Stem Cell Summit, ... medicine stakeholders. The 2014 World Stem Cell Summit will be ... San Antonio, Texas . The ... and development of lifesaving cures and therapies, convening the most ...
    (Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
    (Date:11/18/2014)... (PRWEB) November 18, 2014 ... (PTMEG) Industry is professional and in-depth report ... Polytetrahydrofuran basic information, including its definition, characterization, ... industry outline. This exploration covers the worldwide ... worldwide industry examination covering macroeconomic environment & ...
    Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
    ... 27 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... Jerry McMahon, Ph.D., chairman and CEO,will participate in ... provide a corporate overview, including a discussion of ... product candidate., -- The Thomas Weisel Partners ...
    ... Buckler appointed to Regenerative Medicine editorial board. , ... ... ( www.celltherapygroup.com ) announced today the appointment of its principle consultant, ... Medicine. , , , , ,Published by Future Medicine, Regenerative ...
    ... INVESTMENT BANKING FIRM HAS STRONG BACKGROUND IN BIOTECHNOLOGY, ... or "the Company") (OTC Bulletin Board: SOBM) is ... Partners, Inc. as its financial,advisor to evaluate strategic ... are extremely pleased with the results obtained from ...
    Cached Biology Technology:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 3
    (Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
    (Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
    (Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
    Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
    ... 14 issue of the journal Science shows, for the first ... are driving nearby populations of wild salmon toward extinction. The ... rapidly declining for four years. The scientists expect a 99% ... the infestations continue. The impact is so severe that ...
    ... THE SITUATION: The largest living structures on ... are at risk, the most definitive review yet of the ... In a paper published in the prestigious Science Magazine ... a race against time in preparing coral reefs and the ...
    ... Lab, in collaboration with the Institutes Imaging Center, ... the dynamic protein-protein interactions in the mitogen-activated protein ... to growth and differentiation decisions in all eukaryotic ... in the MAP Kinase Signaling Using Live-Cell Fluorescence ...
    Cached Biology News:Fish farms drive wild salmon populations toward extinction 2Fish farms drive wild salmon populations toward extinction 3Fish farms drive wild salmon populations toward extinction 4It's official: The carbon crisis is lethal for coral reefs 2It's official: The carbon crisis is lethal for coral reefs 3It's official: The carbon crisis is lethal for coral reefs 4Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
    The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
    The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
    ... 2-color staining method for labeling DNA breaks ... cells by flow cytometry. The kit contains ... apoptosis in cells, including positive and negative ... reaction and rinsing buffers for processing individual ...
    The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
    Biology Products: